Key contract manufacturing directions: tablets, solution for infusions, intravenous and intramuscular solutions.
Existing production capacities comply with Russian GMP (as of 2017), Belarus GMP (as of 2016), Chile GMP (2017), ISO 9001 and 14001 requirements.
It is possible to establish a brand-new production line based on the customer requirements and to produce various dosage forms within 1800 m² GxP-compliant production area. Construction of a new production building is possible.
Development of new dosage forms with a focus on further manufacturing in POLYSAN.
Development of drug products nonregistered in Russia with a focus on further manufacturing of the local product.